Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00:02 2023-02-03 pm EST
164.61 USD   -0.56%
02/02Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
BU
02/02Avalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose An Attractive Value Proposition ($ALBT)
AQ
02/02Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : to Participate in the 41st Annual J.P. Morgan Healthcare Conference

12/07/2022 | 11:12am EST

New Brunswick, NJ (December 7th, 2022) -- Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conferenceon Monday, January 9th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

  • Investor Contact:
    RA-JJCUS-InvestorRel@ITS.JNJ.com

    Media Contact:
    Jake Sargent
    (732) 524-1090

Attachments

Disclaimer

Johnson & Johnson published this content on 07 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2022 16:11:04 UTC.


ę Publicnow 2022
All news about JOHNSON & JOHNSON
02/02Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
BU
02/02Avalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose ..
AQ
02/02Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
01/31Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development
MT
01/31Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
PR
01/31With Multiple Shots On Revenue-Generating Goals, Avalon GloboCare Positions For A Break..
AQ
01/31Solid results for Pets at home and UBS: MarketScree..
MS
01/31Idorsia Files European Marketing Authorization Application For Resistant Hypertension T..
MT
01/30Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
PR
01/30Sector Update: Health Care Stocks' Losses Gain Speed Near Monday Close
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 017 M - -
Net income 2022 20 668 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 20,7x
Yield 2022 2,68%
Capitalization 430 B 430 B -
EV / Sales 2022 4,42x
EV / Sales 2023 4,18x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 164,61 $
Average target price 180,90 $
Spread / Average Target 9,90%
EPS Revisions
Managers and Directors
Joaquin Duato Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
James D. Swanson Global Chief Information Officer & Executive VP
Dan Zelem Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-6.29%430 370
ELI LILLY AND COMPANY-9.61%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994
ABBVIE INC.-10.15%256 696